By PPN News Staff
The FDA approved elagolix (Orilissa, AbbVie, Neurocrine Bioscience), the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed to treat women with moderate to severe endometriosis pain.
Elagolix represents the first FDA-approved oral treatment for the management of moderate to severe pain associated with endometriosis in more than a decade, and is expected to be available in early August.